A Study of LOXO-305 in Chinese Participants With Blood Cancer (Including Lymphoma and Chronic Leukemia): Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for A Study of LOXO-305 in Chinese Participants With Blood Cancer (Including Lymphoma and Chronic Leukemia) (NCT04849416), a na phase 2 study. The primary outcome is Primary Analysis Set (PAS): Overall Response Rate (ORR) Assessed by Independent Review Committee.

2. Clinical Question

3. Trial Design

This was a Phase 2, single-group study of oral LOXO-305 in Chinese participants with previously treated blood cancer. The registry lists chronic lymphocytic leukemia or small lymphocytic lymphoma and non-Hodgkin lymphoma among the conditions of interest. The intervention description specifies 200 mg orally once daily, on Days 1 through 28 of a 28-day cycle. Treatment was to continue until progressive disease, a discontinuation criterion, or unacceptable toxicity.

The registry lists no allocation because there was no randomized assignment between study groups. Masking was none. These features make the trial a treatment-group study rather than a randomized comparison. Any change during treatment cannot, from this design alone, be separated from changes that might have occurred over time or under other care.

The primary endpoint was defined for a specific Primary Analysis Set, not simply for every participant described by the broad study title. That set required central confirmation of non-blastoid mantle cell lymphoma, no CNS metastases, prior chemoimmunotherapy and a BTK inhibitor-containing regimen, measurable disease at baseline under Lugano criteria, and at least one dose of study drug. The number of participants meeting these criteria is not reported in the registry record.

The study status is completed. The registry lists a start date of 2021-05-14 and a primary completion date of 2023-04-10. The primary endpoint timeframe extends from first dose to disease progression or subsequent anti-cancer therapy, up to 100 weeks. The planned participation period in the brief description could last up to four years. The registry record does not report further details of the protocol or the reason for each participant's treatment ending.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Overall Study

Reasons for not completing this period:

Analysis population for the primary outcome, as defined in the registry: All participants with Central histologically confirmed non-blastoid MCL, with no CNS metastases and treated with prior chemoimmunotherapy and BTK inhibitor-containing regimen, measurable disease at baseline as assessed using Lugano criteria, and have received at least 1 dose of study drug.

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

Population: All participants who received at least one dose of study drug.

6. Primary Endpoint

The registry lists the primary outcome as Primary Analysis Set (PAS): Overall Response Rate (ORR) Assessed by Independent Review Committee, measured over Date of First Dose to Date of Disease Progression or Subsequent Anti-cancer Therapy (up to 100 Weeks).

The primary endpoint was overall response rate, assessed by an Independent Review Committee. It is the percentage of participants in the defined Primary Analysis Set whose best overall response was complete response or partial response. The endpoint combines those two response categories; it does not by itself describe how long a response lasted or whether disease later progressed.

Response is a binary outcome for this calculation: each participant is counted according to whether their best overall response met the complete-response or partial-response definition. The registry states that response was evaluated by an Independent Review Committee and that measurable disease at baseline was assessed using Lugano criteria. Independent review can help apply response criteria consistently, particularly when treatment assignment and clinical care are not masked, although it does not remove the limitations of having no control group.

Response rate is useful for describing how often a specified degree of tumor response was recorded in the analysis population. It is not equivalent to progression-free survival, overall survival, duration of response, or a comparison of treatment effects. Those are distinct outcomes; the registry lists several of them as secondary measures. The primary timeframe was from first dose to progression or subsequent anti-cancer therapy, up to 100 weeks.

The registry record does not report the number of responders, the response-rate estimate, or the confidence interval. Consequently, the endpoint definition can be explained, but its observed value and statistical precision cannot be assessed from the available record.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

The primary endpoint is a percentage, which is a binary-outcome summary. For each participant in the defined analysis set, the response classification either meets the endpoint definition or does not. The registry defines a qualifying response as best overall response of complete response or partial response. The resulting percentage would describe the share of the analysis set with either qualifying category. The registry record does not report that percentage or the analysis-set denominator.

What does the confidence interval describe?

The registry says that a two-sided 95% confidence interval was calculated using the exact binomial distribution. In general, a confidence interval communicates uncertainty around an estimate under the statistical model and sampling assumptions used. It is not a range containing a known fixed percentage with a stated probability after the data have been observed. Rather, the method is designed to produce intervals that cover the underlying response probability at the stated rate across repeated samples under its assumptions.

The exact binomial approach is a method for a proportion based on binary observations. It is especially useful when response counts are limited or a normal approximation to a proportion may be unreliable. The registry identifies the method but does not report the interval endpoints, the response count, or the denominator. Accordingly, neither the point estimate nor the precision can be reconstructed from the registry record.

Why does the analysis population matter?

The Primary Analysis Set is defined using clinical and treatment-history criteria: central histological confirmation of non-blastoid mantle cell lymphoma, no CNS metastases, prior chemoimmunotherapy and BTK inhibitor-containing treatment, measurable baseline disease under Lugano criteria, and at least one dose of study drug. An estimate calculated in this set applies to participants meeting those criteria. It should not be generalized automatically to every participant enrolled in the broader study or to every population covered by the study title.

In general, analysis populations determine which participants contribute to an endpoint and how missing or ineligible observations are handled. A clearly defined population makes the estimand—the quantity the analysis aims to describe—more interpretable. Here, the definition is recorded, but the number meeting it and any participant-level exclusions are not reported in the registry record.

What does independent review add?

The endpoint was assessed by an Independent Review Committee. In general, independent assessment can reduce the influence of expectations held by the treating team when outcomes require interpretation of clinical or imaging evidence. The study itself was not masked, so independent outcome assessment is a separate design feature from blinding participants or investigators. The registry record does not describe the committee's procedures, the handling of disagreements, or the details of review.

What can a single-group result estimate?

A single-group response estimate describes the frequency of the endpoint among participants receiving the study intervention who qualify for the analysis. It does not directly estimate a treatment difference, because there is no concurrent control group. General statistical comparisons require a reference group or another defensible counterfactual strategy to distinguish treatment effects from background disease course and other influences. No such comparison is described in the registry record.

The registry lists a planning illustration based on an observed effect, with two-sided significance level 0.05, equal allocation between two arms, and a normal approximation. Such planning values, when displayed, are hypothetical design illustrations rather than observed power for this single-group study. The record does not report the numerical illustration values, and the listed two-arm assumptions do not turn the study into a randomized comparison.

How should safety counts be understood statistically?

Adverse-event percentages are descriptive proportions among the participants at risk in the stated category. Serious and other adverse events are separate summaries, and a participant may contribute to both; counts across categories should not be added to infer a unique participant total. In general, event proportions do not identify causation. A comparison of event rates across treatments would require appropriate comparative data and clear definitions of exposure, follow-up, and attribution. Those comparisons are not reported in the registry record.

Finally, statistical precision cannot be judged from a point estimate alone. For the primary endpoint, the registry names a confidence-interval method but supplies no estimate or interval. Neither the strength nor the uncertainty of the primary efficacy finding can therefore be characterized from the posted registry results.

10. Exact Estimates for Each Arm

No two-arm comparison is shown for this trial, but each arm's result can still be summarized with exact interval estimates computed from the posted counts. The Clopper-Pearson interval is exact and conservative; the Wilson interval is a common closer-to-nominal alternative; the Bayesian credible interval uses a uniform Beta(1, 1) prior. For small groups the three can differ noticeably.

R code and output

arm    <- c("PAS - MCL Group")
n      <- c(28)
events <- c(20)
for (i in seq_along(n)) {
  ci <- binom.test(events[i], n[i])$conf.int          # Clopper-Pearson exact interval
  cr <- qbeta(c(0.025, 0.975), 1 + events[i], 1 + n[i] - events[i])   # Bayesian, uniform Beta(1,1) prior
  wi <- (function(x, n) { p <- x / n; z <- qnorm(0.975); d <- 1 + z^2 / n
    c((p + z^2 / (2 * n) - z * sqrt(p * (1 - p) / n + z^2 / (4 * n^2))) / d, (p + z^2 / (2 * n) + z * sqrt(p * (1 - p) / n + z^2 / (4 * n^2))) / d) })(events[i], n[i])
  cat(sprintf("ARM|%s|%d|%d|%.1f|%.1f|%.1f|%.1f|%.1f|%.1f|%.1f\n", arm[i], n[i], events[i], 100 * events[i] / n[i],
              100 * ci[1], 100 * ci[2], 100 * wi[1], 100 * wi[2], 100 * cr[1], 100 * cr[2]))
}

ARM  PAS - MCL Group  28  20  71.4  51.3  86.8  52.9  84.7  52.8  84.7

11. Multiplicity, Missing Data and Analysis Populations

The registry lists multiple secondary outcomes: investigator-assessed overall response, best overall response categories, duration of response, progression-free survival, overall survival, pharmacokinetic measures, and change from baseline in disease-related symptoms and health-related quality of life. These outcomes address different questions and use different measurement scales. The record does not report numerical results for these measures, and the listed number of analyses is zero.

When a study evaluates multiple endpoints or multiple analyses, the chance of at least one apparently unusual finding can increase if each is interpreted as a separate confirmatory test. In general, a prespecified multiplicity strategy can control that risk, for example by defining a hierarchy of tests or adjusting how statistical evidence is judged. The statistical plan for multiplicity, including whether any adjustment or hierarchy was used, is not reported in the registry record. No conclusion about multiplicity control can therefore be drawn.

The primary analysis population is defined, but the number included in it and the handling of missing response assessments are not reported in the registry record. The record also does not state whether participants without evaluable response data were classified in a particular category, excluded, or handled through another method. These details matter because missing outcome information can affect both the denominator and the estimated response proportion.

For time-to-event outcomes listed as secondary measures, the registry record does not provide outcome estimates, event counts, censoring details, or analysis methods. The duration of response, progression-free survival, and overall survival therefore cannot be interpreted from the listed outcome names alone. Similarly, details of the analysis populations used for those outcomes are not reported in the registry record.

12. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Deaths

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 5% reporting threshold.

Most frequent serious adverse event terms

Most frequent non-serious adverse event terms

Serious events with the highest arm-level rate: pneumonia (4.6%), covid-19 (3.4%), death (2.3%), bronchitis (2.3%), covid-19 pneumonia (2.3%).

The safety summary lists 87 participants at risk for serious adverse events and 87 at risk for other adverse events. It reports 33 participants with serious adverse events and 81 with other adverse events. These are separate descriptive categories; the same participant may be represented in both, so the counts must not be added as if they represented different people. The registry also lists 37 deaths. Whether deaths were attributed to treatment, disease, or another cause is not reported in the registry record.

The most frequently listed serious adverse-event terms are pneumonia at 4.6%, Covid-19 at 3.4%, death at 2.3%, bronchitis at 2.3%, Covid-19 pneumonia at 2.3%, and myelosuppression at 1.1%. These percentages describe the listed serious-event terms in this treated group; the record does not provide comparative rates for another treatment group.

Serious adverse events and other adverse events are not interchangeable categories. A serious event is classified using seriousness criteria, whereas an event may be recorded as an adverse event without meeting those criteria. In general, a reported event after treatment is not necessarily caused by treatment. Attribution methods and event-level details are not reported in the registry record. The figures are useful as descriptive safety information, but they do not establish comparative risk or causation.

13. What the Result Does, and Does Not, Mean

The record establishes that the study examined oral LOXO-305 in a single group of Chinese participants with previously treated blood cancers. It defines a primary response outcome for a particular subset with non-blastoid mantle cell lymphoma and specifies independent review and an exact-binomial confidence-interval method. It also describes a daily treatment schedule and reports selected adverse-event counts.

Those details do not establish the observed primary response rate. The registry record does not report the number of complete or partial responses, the response percentage, or its 95% confidence interval. It therefore does not permit a reader to judge the frequency of response in the primary analysis set or how precise that estimate was. The total enrollment of 87 is not a substitute for the unreported size of the primary analysis set.

Even a fully reported response rate from this design would be a description of outcomes in a treated group, not a randomized estimate of benefit relative to another treatment. There was no comparison group, and masking was none. A single-group study cannot by itself separate outcomes associated with the intervention from the natural course of disease, participant selection, prior treatments, or other care.

The broader set of outcomes listed in the registry includes survival, duration of response, pharmacokinetics, symptoms, and quality of life. Their inclusion as planned or tracked measures does not mean their results are available. Numerical results for those secondary outcomes are not reported in the registry record.

The safety counts likewise describe events in the treated group. They do not show that LOXO-305 caused each event, and they do not support a comparison with another treatment. The record does not report event attribution. The most defensible reading is therefore limited: the registry describes the trial's population, treatment, endpoint definitions, and some safety observations, while leaving the primary efficacy estimate and many details needed for broader interpretation unreported.

14. Why This Trial Matters Statistically

This trial illustrates why the definition of an analysis population is central to interpreting an endpoint. Although the study enrolled participants across a broad set of previously treated blood cancers, the primary response analysis was specified for a narrower mantle cell lymphoma population with defined disease features and prior treatment. The primary endpoint consequently addresses that selected group, not necessarily the whole enrolled population.

It also highlights the distinction between a well-defined statistical method and an available statistical result. The record names an Independent Review Committee, a binary response definition, and an exact-binomial confidence interval. Those choices explain how the primary endpoint was intended to be assessed, but they cannot substitute for the response count, denominator, estimate, and interval. Since the numerical primary result is not reported in the registry record, its magnitude and precision remain unknown.

The single-group design is another important statistical feature. It can describe response and adverse events among treated participants, but it does not provide a randomized treatment contrast. This distinction matters when readers encounter efficacy language: a response proportion and a comparative treatment effect are different quantities, with different evidential requirements.

Finally, the safety summary demonstrates why event categories, denominators, and attribution should be read carefully. Serious events, other events, and deaths are not necessarily mutually exclusive, and event occurrence does not itself establish causation. These statistical distinctions help keep registry descriptions in proportion to what the design and reported results can support.

15. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The primary efficacy result is absent from the registry record. The response count, analysis-set denominator, percentage, and 95% confidence interval are not reported. This prevents assessment of both the observed response frequency and its precision. The total enrollment of 87 cannot be assumed to equal the primary analysis population, which has specific eligibility and exposure requirements.

The single-group design has no concurrent control. Consequently, the study cannot estimate a randomized contrast between LOXO-305 and another treatment. The lack of masking is recorded, although the primary endpoint was assessed by an Independent Review Committee. The registry does not describe review procedures or the extent of independence in detail.

Important analysis details are not reported in the registry record, including the number meeting the Primary Analysis Set criteria, missing response-data handling, endpoint-specific analysis populations, and the statistical plan for multiplicity. The numerical results for secondary outcomes are also not reported. This limits evaluation of results beyond the endpoint definitions.

The safety figures are descriptive and lack a comparison group. The record does not report whether events or deaths were considered related to study treatment, nor does the summary provide the clinical detail needed to evaluate individual cases. The treatment schedule and stopping conditions are stated, but participant-level exposure and follow-up details are not reported in the registry record. These limitations constrain causal interpretation and generalization beyond the defined study population.

16. Related Tutorials

17. Related Statistical Calculators

18. Sources

• ClinicalTrials.gov: A Study of LOXO-305 in Chinese Participants With Blood Cancer (Including Lymphoma and Chronic Leukemia) — NCT04849416.
• Registry record last updated 2026-02-06; status last verified 2025-08.
• Results first posted 2024-07-16.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

19. Record Summary

This completed Phase 2 study evaluated oral LOXO-305 in Chinese participants with previously treated blood cancers. The study used a single-group design with no masking. The listed regimen was 200 mg once daily on Days 1 through 28 of a 28-day cycle, continuing until progression, a discontinuation criterion, or unacceptable toxicity.

The primary endpoint was Independent Review Committee-assessed overall response rate in a defined Primary Analysis Set of participants with non-blastoid mantle cell lymphoma and specified clinical and treatment-history characteristics. The registry describes an exact-binomial method for a two-sided 95% confidence interval but does not report the response estimate, interval, or analysis-set size. Secondary measures are listed, but numerical results are not reported in the registry record.

Safety summaries report 33 participants with serious adverse events, 81 with other adverse events, and 37 deaths among 87 at risk in each adverse-event category. These figures are descriptive; treatment attribution is not reported in the registry record. The study start date was 2021-05-14, and the primary completion date was 2023-04-10.